Nivolumab plus chemotherapy appears more effective than brentuximab vedotin plus chemotherapy in patients with advanced stage classic Hodgkin lymphoma.
Researchers have used a geriatric rating scale to show that childhood cancer survivors experience accelerated aging and have a higher risk of premature death than the general population.
Epkinly (epcoritamab-bysp) is approved to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after 2 or more lines of systemic therapy.
Patients who received venetoclax and obinutuzumab, with or without ibrutinib, had better progression-free survival than patients who received chemoimmunotherapy.
New research suggests that carfilzomib increases the risk of heart failure in patients with multiple myeloma, but the risk does not appear to vary between Black and White patients.
Belantamab mafodotin has shown clinical activity and a manageable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma.